Stock Analysis on Net

Medtronic PLC (NYSE:MDT)

$24.99

Economic Value Added (EVA)

Microsoft Excel

EVA is registered trademark of Stern Stewart.

Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Medtronic PLC, economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2025 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial performance, as measured by economic profit, demonstrates a consistent pattern of negative value creation over the observed period. While net operating profit after taxes (NOPAT) fluctuates, it has not been sufficient to cover the cost of capital employed. Invested capital has remained relatively stable, with some variation year to year, influencing the overall economic profit calculation.

Economic Profit Trend
Economic profit consistently registers as a negative value across all reported years, ranging from approximately -3,727 million to -5,291 million. The most negative result occurred in 2021, at -5,291 million. A slight improvement is projected for 2025, with economic profit expected to be -3,727 million, though still negative. This indicates that the company’s returns on invested capital have consistently fallen short of its cost of capital.
NOPAT Analysis
Net operating profit after taxes experienced a decrease from 4,408 million in 2020 to 4,049 million in 2021. It then increased to 4,888 million in 2022 before declining again to 4,151 million in 2023 and further to 3,736 million in 2024. A substantial increase to 4,980 million is projected for 2025. These fluctuations in NOPAT contribute to the variability in economic profit, but do not overcome the cost of capital.
Cost of Capital
The cost of capital has remained relatively stable, fluctuating between 12.37% and 12.90% over the period. A slight decrease is projected for 2025, to 12.37%. This consistent cost of capital, combined with the NOPAT trends, explains the persistent negative economic profit.
Invested Capital
Invested capital shows moderate fluctuations. It increased from 71,146 million in 2020 to 72,405 million in 2021, then decreased to 69,629 million in 2022. It rose again to 70,505 million in 2023 and decreased to 68,670 million in 2024. A projected increase to 70,365 million is anticipated for 2025. These changes in invested capital, while not dramatic, influence the absolute value of economic profit.

In summary, the company has consistently failed to generate economic profit over the analyzed timeframe. While NOPAT is projected to increase in 2025, it is not anticipated to be sufficient to offset the cost of capital and achieve positive economic profit. Continued monitoring of NOPAT and cost of capital is recommended to assess potential strategies for improving value creation.


Net Operating Profit after Taxes (NOPAT)

Medtronic PLC, NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
Net income attributable to Medtronic
Deferred income tax expense (benefit)1
Increase (decrease) in allowances and credit losses2
Increase (decrease) in deferred revenue3
Increase (decrease) in restructuring reserve4
Increase (decrease) in equity equivalents5
Interest expense, net
Interest expense, operating lease liability6
Adjusted interest expense, net
Tax benefit of interest expense, net7
Adjusted interest expense, net, after taxes8
(Gain) loss on marketable securities
Investment income, before taxes
Tax expense (benefit) of investment income9
Investment income, after taxes10
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowances and credit losses.

3 Addition of increase (decrease) in deferred revenue.

4 Addition of increase (decrease) in restructuring reserve.

5 Addition of increase (decrease) in equity equivalents to net income attributable to Medtronic.

6 2025 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

7 2025 Calculation
Tax benefit of interest expense, net = Adjusted interest expense, net × Statutory income tax rate
= × 21.00% =

8 Addition of after taxes interest expense to net income attributable to Medtronic.

9 2025 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

10 Elimination of after taxes investment income.


Net Income Attributable to Medtronic
The net income figures demonstrated variability over the reported periods. Starting at 4,789 million US dollars in April 2020, the net income decreased significantly to 3,606 million by April 2021. It rebounded to 5,039 million in April 2022, indicating a strong recovery. However, a subsequent decline occurred, with net income falling to 3,758 million in April 2023 and slightly decreasing again to 3,676 million in April 2024. The latest period, April 2025, shows an improvement to 4,662 million, suggesting a positive turnaround in profitability.
Net Operating Profit After Taxes (NOPAT)
NOPAT followed a somewhat similar pattern to net income, but with slightly less fluctuation. It decreased from 4,408 million in April 2020 to 4,049 million in April 2021. Then, it increased again to 4,888 million by April 2022. Thereafter, it declined to 4,151 million in April 2023 and further down to 3,736 million in April 2024. The most recent figure in April 2025 reached 4,980 million, representing the highest value among the periods analyzed and indicating improved operational profitability.
Overall Trend Analysis
Both net income and NOPAT exhibited cyclical patterns with notable decreases in 2021 and 2023-2024, followed by recoveries in 2022 and 2025. The volatility suggests the company faced varying operational and market challenges throughout the periods. The recent rise in both metrics in 2025 points towards an enhanced financial performance and operational efficiency. Furthermore, the highest NOPAT value in the final period underscores an improvement in profitability after taxes on operating income, which is a positive indicator for core business performance.

Cash Operating Taxes

Medtronic PLC, cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
Income tax provision (benefit)
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense, net
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).


The financial data reveals notable trends in the tax-related expenses over the observed period.

Income Tax Provision (Benefit)
The income tax provision shows significant fluctuations from 2020 to 2025. Initially, in 2020, there was a tax benefit of -$751 million, indicating a negative tax provision. However, from 2021 onwards, there is a reversal to positive tax provisions, increasing from $265 million in 2021 to a peak of $1,580 million in 2023. Thereafter, the provision decreases to $1,133 million in 2024 and further to $936 million in 2025. This pattern suggests an initial tax advantage followed by growing tax liabilities that begin to moderate in the final years of the period.
Cash Operating Taxes
Cash operating taxes demonstrate a consistent upward trend throughout the period from 2020 to 2023, increasing from $761 million to $1,979 million. In 2024, there is a slight decline to $1,820 million, followed by a further decrease to $1,436 million in 2025. This rise and subsequent decline in cash taxes could reflect operational performance fluctuations or changes in tax strategies and cash management.

Overall, the data indicates evolving tax expenses with an initial tax benefit turning into substantial tax provisions and an increasing trend in cash operating taxes until 2023, followed by a moderate decline in the last two reporting periods.


Invested Capital

Medtronic PLC, invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
Current debt obligations
Long-term debt
Operating lease liability1
Total reported debt & leases
Shareholders’ equity
Net deferred tax (assets) liabilities2
Allowances and credit losses3
Deferred revenue4
Restructuring reserve5
Equity equivalents6
Accumulated other comprehensive (income) loss, net of tax7
Noncontrolling interests
Adjusted shareholders’ equity
Construction in progress8
Available-for-sale debt securities9
Invested capital

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of deferred revenue.

5 Addition of restructuring reserve.

6 Addition of equity equivalents to shareholders’ equity.

7 Removal of accumulated other comprehensive income.

8 Subtraction of construction in progress.

9 Subtraction of available-for-sale debt securities.


The financial data shows several notable trends over the six-year period under review.

Total reported debt & leases
The total reported debt and leases have generally increased, growing from 25,742 million US dollars in April 2020 to 29,626 million US dollars in April 2025. Despite some fluctuations, such as a decrease in 2022, the overall trend is upward, indicating a gradual rise in leverage or financing through debt and leases.
Shareholders’ equity
Shareholders’ equity experienced a slight increase from 50,737 million US dollars in April 2020 to a peak of 52,551 million US dollars in April 2022. However, from that peak, equity declined steadily to 48,024 million US dollars by April 2025. This downward trajectory in equity may reflect distributions to shareholders, asset impairments, or other factors reducing net asset value.
Invested capital
Invested capital saw a modest increase from 71,146 million US dollars in April 2020 to a peak near 72,405 million US dollars in April 2021. Subsequently, it declined to a low of 68,670 million US dollars in April 2024 before rising again to 70,365 million US dollars in April 2025. This pattern suggests some variability in the company's capital investment or asset base, with a general trend of moderate fluctuation rather than sustained growth or contraction.

Cost of Capital

Medtronic PLC, cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2025-04-25).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-04-26).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-04-28).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-04-29).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-04-30).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-04-24).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Medtronic PLC, economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).

1 Economic profit. See details »

2 Invested capital. See details »

3 2025 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The economic spread ratio exhibits a generally negative trend over the observed period, indicating that the company’s return on invested capital is consistently below its weighted average cost of capital. While fluctuations occur, the ratio remains in negative territory throughout the six-year timeframe.

Economic Spread Ratio Trend
The economic spread ratio began at -6.31% in 2020 and deteriorated to -7.31% in 2021, representing the lowest point in the observed period. A slight improvement was noted in 2022, with the ratio increasing to -5.65%. However, this improvement was short-lived, as the ratio declined again to -6.90% in 2023 and further to -7.10% in 2024. A projected improvement is indicated for 2025, with the ratio expected to reach -5.30%.

The economic profit consistently reflects negative values, mirroring the negative economic spread ratio. The magnitude of the economic profit fluctuates, but remains negative across all years. This suggests that the company is not generating sufficient returns to cover the cost of its invested capital.

Relationship between Economic Profit and Invested Capital
Invested capital demonstrates relative stability, ranging between US$68.67 billion and US$72.40 billion. Despite this stability, the consistently negative economic profit indicates that even with a relatively consistent capital base, the company is not achieving adequate profitability relative to its cost of capital. The projected decrease in negative economic profit in 2025 aligns with the anticipated improvement in the economic spread ratio.

The observed trend suggests a persistent challenge in generating returns that exceed the cost of capital. While a potential improvement is projected for 2025, continued monitoring of both the economic spread ratio and economic profit is warranted to assess the sustainability of any positive changes.


Economic Profit Margin

Medtronic PLC, economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
Selected Financial Data (US$ in millions)
Economic profit1
 
Net sales
Add: Increase (decrease) in deferred revenue
Adjusted net sales
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).

1 Economic profit. See details »

2 2025 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted net sales
= 100 × ÷ =

3 Click competitor name to see calculations.


The economic profit margin demonstrates a volatile pattern over the observed period. While fluctuations exist, a general trend towards improvement is apparent in the most recent projections.

Economic Profit Margin Trend
The economic profit margin began at -15.53% in 2020 and deteriorated to -17.53% in 2021, representing the lowest point in the analyzed timeframe. A subsequent improvement was noted in 2022, with the margin increasing to -12.40%. However, this positive movement was interrupted in 2023, as the margin decreased to -15.57%. The latest reported value for 2024 is -15.04%, indicating a slight recovery. Projections for 2025 suggest further improvement, with the economic profit margin expected to reach -11.11%.

The economic profit itself consistently remains negative throughout the period, indicating that the company’s returns are not exceeding its cost of capital. However, the magnitude of the negative economic profit fluctuates alongside the economic profit margin.

Relationship between Economic Profit and Adjusted Net Sales
Adjusted net sales generally increased over the period, moving from US$28,901 million in 2020 to a projected US$33,530 million in 2025. Despite this growth in sales, the negative economic profit persisted, suggesting that increases in sales revenue have not been sufficient to offset the cost of capital. The economic profit margin’s fluctuations suggest that the relationship between sales growth and cost of capital is dynamic.

The projected improvement in the economic profit margin for 2025, while still negative, suggests potential operational efficiencies or changes in capital structure that are positively impacting profitability relative to the cost of capital. Continued monitoring of these trends will be crucial to assess the sustainability of this improvement.